Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p14,200.00. The ...

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £153.18. The ...

DelveInsight's "TIBSOVO Market Size, Forecast, and Market Insight Report" highlights the details around TIBSOVO, the first ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

Market capitalisation stands at Rs 19,771.25 crore. The share touched a 52-week high of Rs 9,049.95 and a 52-week low of Rs 5 ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...